Reuters UK |
AstraZeneca starts final-stage tests on severe asthma drug
Reuters Several firms are racing to develop injectable biotech asthma drugs for patients with severe disease who do not respond well to traditional inhalers, in pursuit of a new market worth a possible $7.5 billion a year. (Reporting by Ben Hirschler, Editing … AstraZeneca Starts Phase III Trial For Asthma Drug Tralokinumab AstraZeneca Starts Late-stage Study Of Tralokinumab – Quick Facts |
View full post on asthma – Google News